Compare Avantis US Small Cap Value ETF (AVUV) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis US Small Cap Value ETF vs BioNTech SE - ADR — how do they compare? Avantis US Small Cap Value ETF trades at $127.35, while BioNTech SE - ADR trades at $93.17 (market cap $23.31B). The key difference: Avantis US Small Cap Value ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| AVUV | BNTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $128.74 | $119.34 |
52-Week Low | $93.93 | $83.89 |
Market Cap | — | $23.31B |
Enterprise Value | — | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVUV trades at $127.03, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bullish trend with moving averages strongly supporting upside momentum while oscillators remain neutral. The ETF has attracted significant attention for its small-cap value exposure, with recent articles highlighting its strong performance relative to broader small-cap indices and its role in diversifying tech-heavy portfolios.
Outlook remains positive as small-cap value continues outperforming growth stocks in 2026. Investment opportunity lies in continued rate cut expectations and regional bank exposure driving returns. Key risks include sensitivity to interest rate changes, higher volatility typical of small-caps, and concentrated US market exposure limiting global diversification benefits.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
